Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement
about
Management of Venous Thromboembolism: Recent Advances in Oral Anticoagulation TherapyDifferential benefit risk assessment of DOACs in the treatment of venous thromboembolism: focus on dabigatranReversal of oral anticoagulationReview article: Venous thromboembolism after total joint replacementProtocol in managing oral surgical patients taking dabigatranThe new oral anti-coagulants and the phase 3 clinical trials - a systematic review of the literaturePerioperative Management of Direct Oral Anticoagulants (DOACs): A Systemic ReviewSafety, tolerability, pharmacodynamics, and pharmacokinetics of rivaroxaban--an oral, direct factor Xa inhibitor--are not affected by aspirinDabigatran etexilate: an oral direct thrombin inhibitor for prophylaxis and treatment of thromboembolic diseases.Fondaparinux sodium in the prophylaxis and treatment of deep vein thrombosis and pulmonary embolism.Direct thrombin inhibitors.Correlation between trough plasma dabigatran concentrations and estimates of glomerular filtration rate based on creatinine and cystatin C.Frequency and predictors of bleeding complications associated with anti-coagulant therapy using dabigatran in Japanese patients with atrial fibrillationNew oral pharmacotherapeutic agents for venous thromboprophylaxis after total hip arthroplastyOral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjectsA proposal for dose-adjustment of dabigatran etexilate in atrial fibrillation guided by thrombin timePharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor.Effects of food on the pharmacokinetics of edoxaban, an oral direct factor Xa inhibitor, in healthy volunteers.Dabigatran etexilate: a review of its use for the prevention of venous thromboembolism after total hip or knee replacement surgery.Approach to the new oral anticoagulants in family practice: part 2: addressing frequently asked questionsContinuous warfarin versus periprocedural dabigatran to reduce stroke and systemic embolism in patients undergoing catheter ablation for atrial fibrillation or left atrial flutter.New options in anticoagulation for the prevention of venous thromboembolism and stroke.Update on anti-coagulation in atrial fibrillation.New oral antithrombotics: focus on dabigatran, an oral, reversible direct thrombin inhibitor for the prevention and treatment of venous and arterial thromboembolic disordersStroke Prevention in Atrial Fibrillation: Where are We Now?Effects of the direct thrombin inhibitor dabigatran on ex vivo coagulation time in orthopaedic surgery patients: a population model analysis.Medical management of venous thromboembolism: what the interventional radiologist needs to knowSafety and efficacy of switching from low molecular weight heparin to dabigatran in patients undergoing elective total hip or knee replacement surgery.Decrease in the oral bioavailability of dabigatran etexilate after co-medication with rifampicin.The Indian consensus guidance on stroke prevention in atrial fibrillation: An emphasis on practical use of nonvitamin K oral anticoagulantsA semi-mechanistic absorption model to evaluate drug-drug interaction with dabigatran: application with clarithromycin.The clinical efficacy of dabigatran etexilate for preventing stroke in atrial fibrillation patientsThe modification of the thrombin generation test for the clinical assessment of dabigatran etexilate efficiency.Practical management of new oral anticoagulants after total hip or total knee arthroplasty.Emergence of new oral antithrombotics: a critical appraisal of their clinical potential.Apixaban in patients with Atrial Fibrillation: A Systematic ReviewRecent developments in the use of oral anticoagulants.Dabigatran etexilate: pivotal trials for venous thromboembolism prophylaxis after hip or knee arthroplasty.Dabigatran etexilate for the prophylaxis of venous thromboembolism after hip or knee replacement rationale for dose regimen.
P2860
Q26766303-9B879AA5-47FA-41BE-BDA5-A42F9B5D385AQ26799710-56B1A850-9F55-4471-9520-4606F34FA1DBQ26827835-6EA8CC3E-1547-4DE5-81B2-C650CD341131Q27006824-1C11DC84-C390-4BEA-827D-7C556A767AC1Q27006890-5F0761C9-E4EB-4D38-8B64-636CB64F77F5Q27497485-7C45D58D-6DFA-4A2D-821E-5A0D32D0A279Q28078177-6D4559DB-871E-410D-8F8F-522742A0923CQ28200198-E7E27E14-C2E0-40F7-ADAD-C3000770899EQ33381801-3B1C0E53-9FE5-4283-8C08-3EB56280B500Q33389966-527CD226-C4A6-4789-991D-C4D4FFEAA992Q33393692-C09587B0-3F50-444B-951E-AD41CF72D960Q33804810-0878CD9A-44C8-46D1-8A5E-60A22FA048A9Q33847039-21DB9819-9C46-4D99-964B-50F3247507F1Q33891915-7321B61B-FA2A-49EA-9D94-0C2AC3A5744FQ34252907-1F379509-E27D-461F-B6F7-568A1629997CQ34285711-A3740780-AD62-4C29-86B1-01E2F399D895Q34571082-D24FB766-56FA-4261-87A3-0E45D9BDCF84Q34611004-54A1B599-8BBC-4242-8034-B45EFA974E7AQ34620374-3B80FE53-234C-4711-BF34-DC6F80FF5AFEQ34638063-5ADD3E8B-F3C1-40BB-81E4-BA841D3BC101Q34666269-788609A7-3167-47F6-9F9D-A2E0B36C4871Q34691799-852BF389-4B76-4213-9728-706B9EFBEC63Q34906214-13DB76C1-3B4E-4913-B03E-343EC3CE9004Q35172841-C6B58F7D-147F-4548-A46C-3AB9DD6C2FF0Q35739671-02471EAC-5879-41EA-BADC-4485D3EE2A86Q35811581-D647F878-AA66-4B22-87B3-1513BA8E7AA6Q35827856-8C76BBC0-ABDE-4BA8-954F-62A3EDCFDF31Q35948292-9BA136CF-BFCE-48D1-8DC0-DEF177973F60Q36321989-F35CABF6-1FD6-4E96-A615-B367A2314EC4Q36336046-15CE0BBC-42A7-4AD9-97DE-1F03E0AE49F0Q36396649-51C99614-0418-4124-89C2-7CB411CA4FACQ36988011-58AD0A15-8679-4C70-A3E3-E28F1C21E37DQ37014482-5608CE59-1EAB-4F0C-8319-04293D6DBE58Q37063974-75CAA2EA-754D-4CEE-93E4-AA3C3F9DCA00Q37338120-B7830BBF-22B5-4A2C-BD09-E211BC9A0154Q37428883-37116ADB-C7B2-4484-AEBF-12BA0869C7E9Q37495983-0E43523A-A140-4DDB-9AED-45251A62435BQ37528463-91D81486-FF55-4FDF-9C74-646145544F51Q37569325-5812D49D-C855-4FBD-B629-1FE36FAFDD02Q37583245-D51FEDEF-2AC1-4D5A-962B-8FAA44A25BB9
P2860
Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement
description
2005 nî lūn-bûn
@nan
2005 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Pharmacokinetic profile of the ...... dergoing total hip replacement
@ast
Pharmacokinetic profile of the ...... dergoing total hip replacement
@en
Pharmacokinetic profile of the ...... dergoing total hip replacement
@nl
type
label
Pharmacokinetic profile of the ...... dergoing total hip replacement
@ast
Pharmacokinetic profile of the ...... dergoing total hip replacement
@en
Pharmacokinetic profile of the ...... dergoing total hip replacement
@nl
prefLabel
Pharmacokinetic profile of the ...... dergoing total hip replacement
@ast
Pharmacokinetic profile of the ...... dergoing total hip replacement
@en
Pharmacokinetic profile of the ...... dergoing total hip replacement
@nl
P2093
P2860
P3181
P356
P1476
Pharmacokinetic profile of the ...... dergoing total hip replacement
@en
P2093
Bengt I Eriksson
Hildegard Stähle
Joachim Stangier
Karin Rathgen
Lennart Ahnfelt
Ola E Dahl
Robbyna Svärd
P2860
P304
P3181
P356
10.1177/0091270005274550
P407
P50
P577
2005-05-01T00:00:00Z